Clinical Trials Directory

Trials / Unknown

UnknownNCT05954247

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 in Healthy Adult Volunteers

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 in Healthy Adult Volunteers Under Fasting Conditions

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
Daewoong Pharmaceutical Co. LTD. · Industry
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWJ1543 in healty adult volunteers.

Detailed description

The study design is a Randomized, Open-label, Oral, Single-dose, Two-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUClast of DWP16001. Secondary endpoints were AUCinf, AUClast, Tmax, t1/2, CL/F, and Vd/F of DWJ1543.

Conditions

Interventions

TypeNameDescription
DRUGDWJ1543DWJ1543
DRUGDWC202216DWC202216

Timeline

Start date
2023-08-01
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2023-07-20
Last updated
2023-07-24

Source: ClinicalTrials.gov record NCT05954247. Inclusion in this directory is not an endorsement.

Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1543 in Healthy Adult Volunteers (NCT05954247) · Clinical Trials Directory